ArticleMedComm2025

Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAF

Junwan Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.